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Abstract
The synthetic control (SC) method has been recently proposed as an alternative to estimate treatment
effects in comparative case studies. An important feature of the SC method is the inferential procedures
based on placebo studies, suggested in Abadie et al. (2010). In this paper, we evaluate the statistical
properties of these inferential techniques. We first show that the graphical analysis with placebos can be
misleading, as placebo runs with lower expected squared prediction errors would still be considered in the
analysis. Then we show that a test based on the the post/pre-intervention mean squared prediction error, as
suggested in Abadie et al. (2010), ameliorates this problem. However, we show that such test can still have
some size distortions, even if we consider a case in which the test statistic has the same marginal distribution
for all placebo runs. Finally, we show that the fact that the SC weights are estimated can lead to important
additional size distortions.
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1 Introduction
In a series of influential papers, Abadie and Gardeazabal (2003), Abadie et al. (2010), and Abadie et al. (2015)
proposed the Synthetic Control (SC) method as an alternative to estimate treatment effects in comparative
case studies when there is only one treated unit. The main idea of the SC method is to use the pre-treatment
periods to estimate weights such that a weighted average of the control units reconstructs the pre-treatment
outcomes of the treated unit. Then they use these weights to compute the counterfactual of the treated
unit in case it were not treated. According to Athey and Imbens (2016), “the simplicity of the idea, and the
obvious improvement over the standard methods, have made this a widely used method in the short period
of time since its inception”. An important feature of the SC method is the inferential procedure based on
placebo studies, suggested in Abadie et al. (2010).
In this paper, we consider the statistical properties of the inferential techniques proposed in Abadie et
al. (2010). In the absence of random assignment, Abadie et al. (2010) and Abadie et al. (2015) interpret
the p-value from their placebo tests as “the probability of obtaining an estimate at least as large as the one
obtained for the unit representing the case of interest when the intervention is reassigned at random in the
data set” (Abadie et al. (2015), page 500). While we agree this is a useful measure, it is important to
evaluate the statistical properties of such tests. Analyzing the SC method in a linear factor model setting as
the one considered in Ferman and Pinto (2016b), we derive the asymptotic distribution of the test statistics
used in these placebo tests. Moreover, we evaluate whether such tests satisfy the conditions for the theory of
randomization inference under an approximate symmetry assumption, developed in in Canay et al. (2014).
We first show that the graphical analysis proposed in Abadie et al. (2010) or a placebo test using the post-
treatment mean squared prediction error (MSPE) as test statistic might lead to important size distortions,
as the distribution of the post-treatment prediction errors for a given permutation might depend on, for
example, the variance of the transitory shocks or the concentration of the SC weights. Such distortions can
arise whether or not the SC estimator is asymptotically unbiased.1 We also note that the strategy suggested
in Abadie et al. (2010) of excluding placebos with a poor pre-treatment fit from the graphical analysis can
be misleading as, under this strategy, placebos with a better pre-treatment fit relative to the treated unit
would still be considered. Since placebos with a lower pre-treatment MSPE would tend to have a less volatile
post-intervention prediction error, this may lead researchers to over-estate the significancy of their results.
We recommend a slight modification in the graphical analysis to take this distortion into account.
1See Ferman and Pinto (2016b) for conditions under which the SC estimator is asymptotically unbiased.
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Then we show that a placebo test using the ratio of post/pre-treatment MSPE as test statistic, also
suggested in Abadie et al. (2010), can ameliorate this problem. If the SC estimator is asymptotically unbiased,
then, under some conditions, the test statistics will have the same asymptotic (marginal) distribution for
all permutations.2 However, even under such conditions, we show that it is not possible to guarantee that
the test is asymptotically valid, as the test statistics are generally not based on functions of the data that
exhibit approximate symmetry, as would be required to apply the results on randomization tests under an
approximate symmetry assumption from Canay et al. (2014). We provide examples in which we can have
some size distortions even when the test statistics for all placebos have the same marginal distribution.
Finally, we show that the placebo test using the ratio of post/pre-treatment MSPE as test statistic can
have important size distortions for at least three additional reasons due to the fact that the SC weights are
estimated. First, if the SC estimator is asymptotically biased, then the expected value of the test statistic
for the treated unit should be higher than for the control units, leading to over-rejection. Interestingly,
our Monte Carlo (MC) simulations suggest that this over-rejection may appear even when the variance of
the transitory shocks is small, in which case the pre-treatment fit should be good and the bias of the SC
estimator should be small. This happens because, in this case, the variance of the SC estimator would be
relatively small as well, so even a small bias could generate relevant size distortions. Second, we show that
the post/pre ratio of MSPE may fail to properly correct the marginal distribution of the test statistics for
a finite number of pre-treatment periods (T0). This might happen because, with small T0, the model might
overfit the pre-treatment MSPE, so it might not provide a proper correction for the post-treatment MSPE.
Finally, the fact that the SC method should only be used when there is a good pre-treatment fit while the
placebos would be considered regardless of that can also lead to over-rejection. This happens because the
test statistic of the treated unit would be conditional on a denominator close to zero, while the test statistic
for the placebos would not.
A few recent papers analyzed in detail the placebo tests proposed in Abadie et al. (2010). Firpo and
Possebom (2016) formalize the placebo test for the case where treatment is randomly assigned. In this
case, the inference method suggested in Abadie et al. (2010) would provide valid inference for unconditional
tests. Differently from Firpo and Possebom (2016), our paper considers the asymptotic properties of the
placebo tests when we relax the hypothesis of random assignment. Also, even under random assignment,
2This will be the case if linear combinations of the transitory shocks and common factors are stationary, serially uncorrelated,
and i.i.d. across units up to a scale parameter. We derive an alternative test statistic that guarantees the same asymptotic
expected value and variance for all permutations under weaker conditions.
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we can consider hypothesis testing conditional on the data on hand.3 Hahn and Shi (2016) point out to
the possibility of severe size distortions in placebo tests for the SC method in MC simulations. They focus,
however, on a test statistic based on the post-intervention MSPE. We show that such severe size distortions
can be strongly attenuated once we consider the post/pre ratio of MSPE as test the statistic, although
the test may still present size distortions even if the test statistics for all placebos have the same marginal
distribution. Finally, Ando and Sa¨vje (2013) argue that the placebo test proposed by Abadie et al. (2010) is
generally not valid and derive an alternative inference method. Differently from Ando and Sa¨vje (2013), we
consider the asymptotic properties of Abadie et al. (2010) placebo tests when the number of pre-intervention
is large. Moreover, Ando and Sa¨vje (2013) focus on the case in which the placebo test could have size
distortions because the SC estimator would fail to reconstruct the factor loadings of the “treated” unit for
some placebo runs, while we show that there might be size distortions even if we consider weights that satisfy
this condition for all placebo runs.4
The remainder of this paper proceeds as follows. We present a brief review of the SC method in Section 2.
In Section 3, we show that the placebo tests might have size distortions even when we consider an “infeasible”
SC estimator that uses weights that correctly reconstruct the factor loadings of the treated unit. In Section
4, we consider additional sources of size distortions that are generated by the fact that the SC weights are
estimated. We conclude in Section 5.
2 A Brief Review of The Synthetic Control Model
2.1 Setting
We consider the SC estimator in a linear factor models setting, as in Ferman and Pinto (2016b). Suppose we
have a balanced panel of J + 1 units indexed by i observed on t = 1, ..., T periods. We want to estimate the
treatment effect of a policy change that affected only unit j = 1 from period T0 + 1 ≤ T to T . The potential
outcomes are given by:

yit(0) = δt + λtµi + it
yit(1) = αit + yit(0)
(1)
3See Ferman and Pinto (2016a) for details on why conditional tests should be preferable when there are few treated units.
4Carvalho et al. (2015), Carvalho et al. (2016) and Powell (2016) consider extensions of the SC estimator, and derive large
sample inferential techniques for hypothesis testing regarding the average effect across the post-treatment periods when both
the number of pre- and post-treatment periods go to infinity. In this paper, we focus on the case in which the number of
pre-treatment periods is large, but the number of post-treatment periods is finite.
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where δt is an unknown common factor with constant factor loadings across units, λt is a (1× F ) vector of
common factors, µi is a (F × 1) vector of unknown factor loadings, and the error terms it are unobserved
transitory shocks. We only observe yit = dityit(1)+(1−dit)yit(0), where dit = 1 if unit i is treated at time t.
Note that the unobserved error uit = λtµi + it might be correlated across units due to the presence of λtµi.
Since we hold the number of units (J + 1) fixed and look at asymptotics when the number of pre-treatment
periods goes to infinity, we treat the vector of unknown factor loads (µi) as fixed and the common factors
(λt) as random variables. In order to simplify the exposition of our main results, we consider the model
without observed covariates Zi.
An important feature of our setting is that the SC estimator is only well defined if it actually happened
that one unit received treatment in a given period. We define D(1, T0) as a dummy variable equal to 1 if
unit 1 is treat after T0 while all other units do not receive treatment.
5 Assumption 1 makes it clear that the
sample a researcher observers when considering the SC estimator is always conditional on the fact that one
unit was treated in a given period.
Assumption 1 (conditional sample) We observe a realization of {y1t, ..., yJ+1,t} for t = 1, ..., T condi-
tional on D(1, T0) = 1.
We also impose that the treatment assignment is not informative about the first moment of the transitory
shocks.
Assumption 2 (transitory shocks) E[jt|D(1, T0)] = E[jt] = 0
Assumption 2 implies that, once we condition on the common factors λt, the transitory shocks are
mean-independent from the treatment assignment. This assumption implies that E[yjt(0)|D(1, T0), λt] =
E[yjt(0)|λt] and E[yjt(1)|D(1, T0), λt] = E[yjt(1)|λt]. Note that this assumption excludes the possibility that
treatment assignment is informative about the transitory shocks. However, we still allow for the possibility
that the treatment assignment to unit 1 is correlated with the unobserved common factors. More specifically,
we allow for E[λt|D(1, T0)] 6= E[λt].
We define Φ1 as the set of weights such that a weighted average of the factor loadings of the control units
reconstructs the factor loadings of the treated unit. That is:
Φ1 =
w∗1 ∈ RJ | µ1 = ∑
j 6=1
wj1
∗
µj ,
∑
j 6=1
wj1
∗
= 1, and wj1
∗ ≥ 0

5That is, one can think of D(1, T0) as a product between two indicator variables, one for the event that the treated unit is
unit 1, and the other one that the treatment starts after T0.
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where wj1 is the weight associated to unit j when we re-construct the factor loadings of unit 1. Note that it
may be that Φ1 = ∅.
If we knew w∗1 ∈ Φ1, then we could consider an infeasible SC estimator using these weights, αˆ∗1t =
y1t −
∑
j 6=1 w
j
1
∗
yit. For a given t > T0, we have that:
αˆ∗1t = y1t −
∑
j 6=1
wj1
∗
yit = α1t +
1t −∑
j 6=1
wj1
∗
jt
 (2)
Therefore, under Assumption 2, we have that E[αˆ∗1t|D(1, T0) = 1] = α1t, which implies that this infeasible
SC estimator is unbiased.
2.2 The SC estimator
The main idea of the SC method consists of estimating the SC weights ŵ1 = {wˆj1}j 6=1 using information on
the pre-treatment period, so that we can construct the SC estimator αˆ1t = y1t −
∑
j 6=1 wˆ
j
1yjt for t > T0.
Abadie et al. (2010) suggest a minimization problem to estimate these weights using the pre-intervention
data. They define a set of K economic predictors where X1 is a (K × 1) vector containing the economic
predictors for the treated unit and X0 is a (K × J) matrix of economic predictors for the control units.6
The SC weights are estimated by minimizing ||X1 −X0w1||V subject to
∑J+1
i=2 w
j
1 = 1 and w
j
1 ≥ 0, where
V is a (K ×K) positive semidefinite matrix. They discuss different possibilities for choosing the matrix V ,
including an iterative process where V is chosen such that the solution to the ||X1 −X0w1||V optimization
problem minimizes the pre-intervention prediction error. In other words, let YP1 be a (T0× 1) vector of pre-
intervention outcomes for the treated unit, while YP0 be a (T0×J) matrix of pre-intervention outcomes for the
control units. Then the SC weights would be chosen as ŵ1(V
∗) such that V ∗ minimizes ||YP1 −YP0 ŵ1(V )||.
Here we focus on the specification that uses all pre-treatment outcome lags as economic predictors. In
this case, the optimization problem to derive the SC weights simplifies to:
ŵ1 = argmin
w∈W
1
T0
T0∑
t=1
y1t −∑
j 6=1
wj1yjt
2
where W = {w1 ∈ RJ |wj1 ≥ 0 and
∑
j 6=1 w
j
1 = 1}.
Ferman and Pinto (2016b) show that the SC weights will, in general, converge to weights that do not
6Economic predictors can be, for example, linear combinations of the pre-intervention values of the outcome variable or
other covariates not affected by the treatment.
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reconstruct the factor loadings of the treated unit. That is, in general, ŵ1 →p w¯1 /∈ Φ1, even if Φ1 6= ∅. In
a setting in which the pre-treatment averages of the first and second moments of the common factors and
transitory shocks converge, they show that SC estimator will converge to:
αˆ1t = y1t −
∑
j 6=1
wˆj1yit
d→ α1t +
1t −∑
j 6=1
w¯j1jt
+ λt
µ1 −∑
j 6=1
w¯j1µj
 (3)
where, in general, µ1 6=
∑
j 6=1 w¯
j
1µj . This implies that the SC estimator will be asymptotically biased when
the fact that treatment was assigned to unit 1 after time T0 is informative about the unobserved common
factors.
Ferman and Pinto (2016b) also show that, in a setting in which a subset of the common factors include
a linear time trend or I(1) processes, then the SC weights will converge to weights that reconstruct the
factor loadings associated to the linear time trend of to the I(1) processes. In this case, the SC estimator
would be asymptotically unbiased even if treatment assignment is informative about these non-stationary
common factors. However, the SC weights would still fail to reconstruct the factor loadings associated to the
stationary common factors, so it will be asymptotically biased if treatment assignment is informative about
the stationary common factors.
2.3 Inference: placebo tests
As argued in Abadie et al. (2010), large sample inferential techniques are not well suited to comparative case
studies when the number of units in the comparison group is small.7 They propose instead placebo tests
where they apply the SC method to every potential control in the sample. First, they consider a graphical
analysis where they compare the post-treatment prediction error of the SC estimator with the prediction
error for each of SC placebo estimator. Then they consider whether the prediction error when one considers
the actual treated unit is “unusually” large relative to the distribution of prediction errors for the units in
the donor pool. Note that the graphical analysis suggested in Abadie et al. (2010) does not provide a clear
decision rule on whether the null hypothesis should be rejected. Still, this analysis would implicitly reject
the null when the post-intervention MSPE for the SC estimate is greater than the post-intervention MSPE
for the placebo estimates. We consider, therefore, the post-intervention MSPE as the test statistic in order
7Carvalho et al. (2015), Carvalho et al. (2016) and Powell (2016) rely on large sample inferential techniques. Instead of
testing the null hypothesis of no effect for all post-treatment periods, they test whether the average effect across time is equal to
zero. If both the number of pre- and post-intervention periods is large, then they are able to derive the asymptotic distribution
of the estimator. This method would not work if one wants to test the null of no effect for all post-treatment periods or if the
number of post-intervention periods is finite.
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to analyze potential distortions in such graphical analysis:
tposti =
1
T − T0
T∑
t=T0+1
yit −∑
j 6=i
wˆji yjt
2 (4)
Then they also suggest a placebo test comparing the post/pre-treatment MSPE as test statistic.
tratioi =
1
T−T0
∑T
t=T0+1
[
yit −
∑
j 6=i wˆ
j
i yjt
]2
1
T0
∑T0
t=1
[
yit −
∑
j 6=i wˆ
j
i yjt
]2
Abadie et al. (2010) and Abadie et al. (2015) recognize that the assumptions required in the classical
randomization inference setting (in particular, random treatment assignment) are rather restrictive in the
SC setting. Still, they argue that it is possible to interpret the p-values from their placebo tests as “the
probability of obtaining an estimate at least as large as the one obtained for the unit representing the case
of interest when the intervention is reassigned at random in the data set” (Abadie et al. (2015), page 500).
While we agree that this interpretation of the placebo tests p-values is useful, it is important to consider the
statistical properties of such tests.
3 Placebo tests with “infeasible” SC estimator
We start considering the properties of the placebo test using an infeasible SC estimator which uses weights
that correctly reconstruct the factor loadings of the treated unit. This way we are able to disentangle the
potential problems that arise due to the estimation of the SC weights as compared to problems that would
arise even for an infeasible SC estimator.
3.1 Graphical analysis & post-MSPE
We consider first the graphical analysis suggested in Abadie et al. (2010). As mentioned in Section 2.3, the
graphical analysis would suggest that the treatment effect is different from zero if tpost1 is “unusually” large
relative to the distribution of {tposti }J+1i=1 . Assuming that we know w∗i ∈ Φi for all i = 1, ..., J + 1, then we
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have that:8
tposti =
1
T − T0
T∑
t=T0+1
it −∑
j 6=i
wji
∗
jt
2 (5)
There are at least three reasons why this test statistic might not have the same (marginal) asymptotic
distribution for all permutations. First, the transitory shock might be heteroskedastic. Ferman and Pinto
(2016a) show that this would usually be true in the Differences-in-Differences setting if we have unit x time
aggregate values and there is variation in the number of observations per unit. This would be the case, for
example, if one uses the Current Population Survey (CPS). Note that, in this case, tposti would tend to attain
higher values when the treated unit is small relative to the units in the donor pool. Second, even if the
transitory shock is homoskedastic, the variance of it−
∑
j 6=i w
j
i
∗
jt will depend on the weights {wji
∗}j 6=i. If
the weights for unit i are more concentrated around a few units in the donor pool, then the variance of tposti
should be higher than if the weights were more evenly distributed. Finally, tposti would not have the same
distribution as tpost1 if, for some i, Φi = ∅. In this case, the distribution of t
post
i would also depend on the
common factors λt. Hahn and Shi (2016) provide MC simulations showing that a permutation test using
tposti as test statistic may severely over-reject under the null, even if one uses an infeasible SC estimator that
relies on weights that correctly reconstruct the factor loadings of the treated unit.
Abadie et al. (2010) correctly noticed that the outcome variable may not be well reproduced for some units
by a convex combination of the other units for the pre-intervention periods, and that the post-intervention
MSPE for these units should be high as well. For this reason, they exclude placebos in which the pre-
intervention MSPE is 20 times (or 5 times) larger than the pre-intervention MSPE for the treated unit.
Note that, considering the infeasible SC estimator and using that wi ∈ Φi for all i, then the prediction error
would be it−
∑
j 6=i w
j
i
∗
jt whether time t is either pre- or post-intervention. Therefore, assuming that it is
stationary, then it would be likely that, in our setting, tposti under the null has the same asymptotic marginal
distribution as tpost1 if the pre-intervention MSPE for unit i and unit 1 are similar. Note, however, that Abadie
et al. (2010) procedure only excludes placebos with pre-intervention MSPE higher than the pre-intervention
MSPE for the treated unit. Therefore, if there are many placebos with lower pre-intervention MSPE, then
8Ando and Sa¨vje (2013) argue that in most applications it would not be reasonable to assume that this assumption is valid
for all i. We believe that this condition might be reasonable in some applications. For example, this condition is satisfied if we
have different groups of units where time trends are different across groups but parallel within groups, as considered in Ferman
et al. (2016) and Ferman and Pinto (2016b). We analyze this case in detail in our MC simulations. In this case, the main idea
of the SC estimator would be to select the control units that follow the same time trend as the treated unit. We consider below
the implications in case assumption 1 is not valid for all i.
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the test would over-reject the null since tpost1 would tend to attain larger values. In this case, Abadie et al.
(2010) graphical analysis could be misleading, even if we consider weights that in that correctly reconstruct
the factor loadings of the treated unit.
One possibility to ameliorate this problem is to re-scale the post- and pre-intervention prediction errors
of the control units using the pre-intervention MSPE. More specifically, for placebo i, we can divide its
prediction error by its the squared root of its pre-intervention MSPE, and multiply it by the squared root
of unit 1 pre-intervention MSPE. As described in detail below in Section 3.2, under some conditions, this
strategy would imply in prediction errors with the same variance for all placebos. Note that this strategy
precludes the necessity of choosing arbitrary cut-offs for the exclusion of ill-fitting placebo runs.9
3.2 Post/pre-MSPE ratio
A second inference procedure suggested by Abadie et al. (2010) is a placebo test using the ratio of post/pre-
intervention MSPE (tratioi ). According to them, “the main advantage of looking at ratios is that it obviates
choosing a cut-off for the exclusion of ill-fitting placebo runs”.
Assuming again an infeasible SC estimator which uses weights that correctly reconstruct the factor
loadings of the treated unit, we have that:
tratioi =
1
T−T0
∑T
t=T0+1
[
it −
∑
j 6=i w
j
i
∗
jt
]2
1
T0
∑T0
t=1
[
it −
∑
j 6=i w
j
i
∗
jt
]2 (6)
Note that, if we let T0 →∞, then:
tratioi →d
1
T − T0
T∑
t=T0+1
 it −∑j 6=i wji ∗jt√
var(it −
∑
j 6=i w
j
i
∗
jt)
2 (7)
Therefore, tratioi will have the same asymptotic (marginal) distribution for all i if Qit = it −
∑
j 6=i w
j
i
∗
jt
is stationary, serially uncorrelated, and i.i.d. across i up to a scale parameter. If we assume that
E[Q4it]
(E[Q2it])
2 is
constant, and still maintain that errors are serially uncorrelated and stationary, then the test statistic has,
asymptotically, the same expected value and variance for all placebos.
9If we constraint the SC unit to convex combinations of the control units, as in Abadie et al. (2010), then there is no guarantee
that the pre-treatment prediction error will have mean zero. This will be particularly relevant for cases in which the SC weights
are estimated or when Φj = ∅ for some j. An alternative would be to use a demeaned SC estimator, as recommended in
Ferman and Pinto (2016b). This is equivalent to relaxing the no-constant constraint, as presented in Doudchenko and Imbens
(2016).
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Note that if we relax the assumption that errors are serially uncorrelated, then there is no guarantee that
the variance of tratioi will be the same for all i. This happens because the denominator in 7 will not correctly
re-scale the variance of the post-intervention MSPE, due to the serial correlation. Instead, we can construct
an alternative test statistic t˜i that has asymptotically the same expected value and variance for all placebos.
Define Si =
1
T−T0
∑T
t=T0+1
[
it −
∑
j 6=i w
j
i
∗
jt)
]2
. We can use:
t˜i =
1
T−T0
∑T
t=T0+1
[
yit −
∑
j 6=i w
j
i
∗
yjt
]2
− Ê[Si]√
̂var(Si)
(8)
where Ê[Si] is an estimator for E[Si] and ̂var(Si) is an estimator for var[Si]. With large T0, we can construct
a new time serie Sit =
1
T−T0
∑t+T−T0
t′=t
[
yit′ −
∑
j 6=i w
j
i
∗
yjt′
]2
using the pre-treatment periods and calculate
Ê[Si] and ̂var(Si). In Appendix A.1, we provide conditions such that these are consistent estimators, and
show that, in this case, the asymptotic distribution of t˜i has expected value equal to zero and variance equal
to 1 for all placebos.10
The test statistics tratioi and t˜i help prevent that test statistics for different placebos have wildly different
asymptotic (marginal) distributions, which could generate severe size distortions. However, it is important
to note that, even if the test statistics for all placebos have the same asymptotic (marginal) distributions,
it is not possible to guarantee that the placebo test is asymptotically valid. Following Canay et al. (2014),
such test would be asymptotically valid if the test statistics are based on a function of the data that exhibits
approximate symmetry. In the SC setting, this will not generally be the case, because the SC estimator
is a function of transitory shocks of the treated and control units, which induces correlation between test
statistics in different permutations. With fixed J , this correlation will not vanish, even when T0 → ∞, as
noticed in Powell (2016). We provide now examples in which the test statistics can have the same asymptotic
distribution for all permutations, but we still can have size distortions.
Again, we assume that we know wi ∈ Φi and that we know the variance of yit −
∑
j 6=i w
j
i yjt. Consider
first a model with two common factors, λt = (λ
1
t , λ
2
t ), where µi = (1, 0) for i = 1, 2, 3 and µi = (0, 1) for
i = 4, ..., 20. Assume also that it
i.i.d.∼ N(0, 1) for all i and t. An (infeasible) SC estimator for the treatment
effect at time t in this model for units i = 1, 2, 3 uses the average of the other 2 units that have the same
factor loadings to construct the SC estimator, while for units i = 4, ..., 20 it uses the average of the the other
10Note that this test statistic can also be used with the feasible SC estimator. In this case, we also need to impose assumptions
on the time series of the common factors λt.
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16 units that have the same factor loadings. Now consider the vector
(
αˆ1√
var(αˆ1)
, αˆ2√
var(αˆ2)
, ..., αˆ20√
var(αˆ20)
)′
,
where αˆj is the SC estimator using unit j as treated. For all i,
αˆi√
var(αˆi)
∼ N(0, 1). However:
cov
(
αˆi√
var(αˆi)
,
αˆk√
var(αˆk)
)
=

−0.5 if i ∈ {1, 2, 3} and k ∈ {1, 2, 3}/{i}
0 if i ∈ {1, 2, 3} and k ∈ {4, ..., 20}
−0.06 if i ∈ {4, ..., 20} and k ∈ {4, ..., 20}/{i}
(9)
Therefore, while all elements in this vector have the same marginal distribution, the conditional distri-
butions are not the same for all placebos. This implies a mild under-rejection of 4.3% for a 5% test when
we consider unit 1 as treated.11 Intuitively, this happens because the high correlation between αˆ1var(αˆ1) and
αˆ2
var(αˆ2)
implies that, when αˆ1var(αˆ1) is extreme, the realization of
αˆ2
var(αˆ2)
is likely to be extreme as well. On
the contrary, when a realization of αˆivar(αˆi) for i > 3 is extreme, it does not imply that the realizations of
other αˆkvar(αˆk) for k 6= i are likely to be extreme as well. Of course, if we do have random assignment, then
this placebo test would still have the correct size for unconditional tests, as the conditions for randomiza-
tion inference would be satisfied (see Fisher (1935)). However, if the probability that a unit with the same
characteristics as unit 1 is more likely to receive treatment, then we would have under-rejection.
We now show another example in which heteroskedasticity can also generate size distortions, even if the
linear factor structure is symmetric. Assume now that we have 20 units in total. We have 5 common factors
λt = (λ
1
t , ..., λ
5
t ), and µi = (1, 0, 0, 0, 0) for units i = 1, ..., 4, µi = (0, 1, 0, 0, 0) for units i = 5, ..., 8, and so on.
Consider that var(1t) = σ
2 and var(it) = 1 for all i > 1. We calculate the infeasible SC estimator αˆi as
the minimum variance estimator such that wi ∈ Φi.12 In this case, a higher σ2 implies a lower correlation
between αˆ1 and αˆi for i ∈ {2, 3, 4}. This happens because, when σ2 is higher, then the SC estimator αˆi for
i ∈ {2, 3, 4} will assign lower weights for y1t. If σ2 = 2, then rejection rate is 5.3%, while rejection rate is
5.5% if σ2 = 5. If σ2 < 1, then we increase the correlation between αˆ1 and αˆi for i ∈ {2, 3, 4}. If σ2 = 0.5,
then rejection rate is 4.6%, while if σ2 = 0.1, then rejection rate is 4%. Again, these results suggest that
heteroskedasticity can generate size distortions in the permutation test even when the marginal distributions
of the test statistics are the same for all permutations. However, based on our examples, size distortions are
relatively mild even if we consider a highly heteroskedastic model.
11This rejection rate was calculated based on 10.000.000 MC simulations.
12In this case, if i = 1 or i > 4, then we construct the SC unit as the simple average of the other units that have the same
factor loading as the treated unit. If i ∈ {2, 3, 4}, then we construct the SC unit assigning weight equal to 1
2σ2+1
for unit 1 and
σ2
2σ2+1
for the other two units.
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4 Placebo tests with estimated SC weights
The results from Section 3 show that, even considering an infeasible SC estimator that correctly reconstructs
the factor loadings of the treated unit, the placebo tests may have (mild) size distortions. We now con-
sider additional problems that may arise due to the fact that the SC weights are estimated. We consider
three possibilities: (i) when the SC estimator is asymptotically biased; (ii) when the transitory shocks are
heteroskedastic, and; (iii) when the SC analysis is conditional on a good pre-treatment fit.
For these three cases, we consider MC simulations of a linear factor model in which all units are divided
into groups that follow different time trends. In our first DGP, we consider a model with stationary common
factors:
Y 0j,t = δt + λ
k
t + j,t (10)
for some k = 1, ...,K. We consider the case in which J + 1 = 20 and K = 10. Therefore, units 1 and 2 follow
the trend λ1t , units 3 and 4 follow the trend λ
2
t , and so on. We consider that λ
k
t is normally distributed with
variance equal to one, and we vary the serial correlation of λt and the variance of j,t ∼ N(0, 0.1).
In our second DGP, we modify the linear factor model such that a subset of the common factors is I(1).
In this case, we consider DGP which includes a non-stationary trend φrt that follows a random walk:
Y 0j,t = δt + λ
k
t + φ
r
t + jt (11)
for some k = 1, ...,K and r = 1, ..., R. We consider in our simulations K = 10 and R = 2. Therefore, units
j = 2, ..., 10 follow the same non-stationary path φ1t as the treated unit, although only unit j = 2 also follows
the same stationary path λ1t as the treated unit.
In both models, we impose that there is no treatment effect, i.e., Yj,t = Y
0
j,t = Y
1
j,t for each time period
t ∈ {1, ..., T0}. We fix the number of post-treatment periods T − T0 = 10 and we vary the number of
pre-intervention periods in the DGPs, T0 ∈ {12, 32, 100, 400}.
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4.1 SC estimator is asymptotically biased
Once we consider that the SC estimator relies on estimated weights, we have that:
tratioi =
1
T−T0
∑T
t=T0+1
[
yit −
∑
j 6=i wˆ
j
i yjt
]2
1
T0
∑T0
t=1
[
yit −
∑
j 6=i wˆ
j
i yjt
]2
d→ 1
T − T0
T∑
t=T0+1
 it −∑j 6=i w¯ji jt + λt(µi −∑j 6=i w¯jiµj)√
var(it −
∑
j 6=i w¯
j
i jt + λt(µi −
∑
j 6=i w¯
j
iµj))
2 (12)
where ŵji
p→ w¯ji .
Following Ferman and Pinto (2016b), it will generally be the case that w¯i /∈ Φi, so µi 6=
∑
j 6=i w¯
j
iµj . As
a consequence, the SC estimator will be asymptotically biased if the fact that unit 1 was treated after T0 is
informative about the common factors. In this case, since the test statistic depends on the common factors
even when T0 → ∞, the expected value of the test statistic of the treated unit will usually be higher than
the expected value of the placebo test statistics, leading to over-rejection.
We explore the implications of the bias of the SC estimator for the placebo tests in the MC simulations
described above. We set var(it) = σ
2
 ∈ {0.1, 0.5, 1} and we set λt as an AR(1) process with 0.5 serial
correlation. Note that the permutation test would work in this case if we were able to use w∗i ∈ Φi.13
In columns 1 to 3 of Table 1 we present rejection rates in a stationary model when we have that
E[λ1t |D(1, T0) = 1] = 1 for t > T0, while in columns 4 to 6 we present rejection rates when E[λ1t |D(1, T0) =
1] = 2 for t > T0. As expected, the placebo test over-rejects the null, as the expected value of the test statistic
is higher for the treated unit. Interestingly, we find the largest over-rejection when σ2 = 0.1, in which case
we found that the misallocation of weights (and, therefore, the asymptotic bias) should be relatively lower.
This happens because, while the bias is lower in this case, the variance of the SC estimator is also lower. We
present in columns 7 to 12 of Table 1 the same results for the non-stationary model. The placebo test still
over-rejects the null, but not as much as in the stationary model. The reason is that the variance of the SC
estimator is higher in the non-stationary model, due to the small discrepancy in the factor loadings of the
treated and SC units associated with the non-stationary common factor for a fixed T0. Overall, these results
suggest that, when the SC estimator is biased, then the placebo test can over-reject the null even when the
bias of the SC estimator is relatively small.
13In this case, the infeasible SC estimator is equal to yit − yi′t, where i′ is the pair that follows the same parallel trend as i.
Therefore, for all i, the correlation between i and j will be equal to one if j is the pair of j, and zero otherwise.
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4.2 Heteroskedasticity with finite and large T0
We consider next whether heteroskedasticity can generate size distortions in this model. In this case, we
consider the same model where J + 1 = 20 units are divided into 10 groups of 2 units each, but we set the
variance of the transitory shocks of the treated unit equal to 0.1, while the variance of the transitory shocks
of the control units is equal to one. We present in column 1 of Table 2 rejection rates when transitory shocks
and common factors are serially uncorrelated, using the test statistic proposed in Abadie et al. (2010) (tratioi ).
With T0 = 1000, rejection rate is around 5%. This was expected given that, with serially uncorrelated
transitory shocks and common factors, tratioi would have the same asymptotic marginal distribution for all
placebos.14 With finite T0, however, our simulation results suggest that the size distortion can actually be
relevant even if the common factors are serially uncorrelated. We over-reject the null when the treated unit
has a lower variance. Note that, with a finite T0, t
ratio
i is given by:
tratioi =
1
T−T0
∑T
t=T0+1
[
it −
∑
j 6=i ŵ
j
i jt + λt(µi −
∑
j 6=i ŵ
j
iµj)
]2
1
T0
∑T0
t=1
[
it −
∑
j 6=i ŵ
j
i jt + λt(µi −
∑
j 6=i ŵ
j
iµj)
]2 (13)
While both numerator and denominator of the test statistic depend on a linear combination of common
and transitory shocks, the weights ŵji are chosen as to minimize the denominator. If T0 is not large enough
relative to J , we might “over-fit” the model. As a consequence, the denominator (in-sample prediction
error) would not provide an adequate correction for the variance of the numerator (out-of-sample prediction
error), so the marginal distribution of the test statistic would depend on the variance of the treated unit.
One possible solution to this problem is to use pre-treatment periods not used in the estimation of the SC
weights in the denominator. However, this implies not using all pre-treatment outcome lags as economic
predictors exactly when T0 is small. Also, the variance of the denominator should be large if one leaves out
only a few pre-treatment lags, which would imply in a test with low power. Another possible solution might
be to avoid over-fitting using a different method to estimate the SC weights that takes into account the fact
that the number of parameters might be large relative to the number of pre-treatment periods. Doudchenko
and Imbens (2016) consider the use of regularization methods such as best subset regression or LASSO to
estimate the SC weights.
We present in column 3 of Table 2 rejection rates when common factors follow an AR(1) process with
14Differently from the infeasible SC estimator, the actual SC estimator will not assign 100% of the weight to the pair of the
treated unit, even when T0 →∞. Therefore, there is no guarantee the the placebo test is asymptotically valid even in this case.
Still, our MC simulations suggest that asymptotic size distortions are negligible for this particular DGP.
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serial correlation equal to 0.9. In this case, the test statistic tratioi does not have the same asymptotic marginal
distribution for all placebos. The problem is that the test statistic tratioi does not properly take into account
the serial correlation in the common factors. This implies an over-rejection even when T0 is large. In this
case, an alternative test statistic, t˜i, that properly corrects the marginal distributions of the test statistics
when T0 → ∞ provides rejection rates close to 5% when T0 is large (column 4 of Table 2). With finite
T0, however, we have over-rejection when the treated unit has a lower variance, whether we use t
ratio
i or t˜i,
as in the case with serially uncorrelated common factors. The results using the non-stationary DGP are
qualitatively similar (columns 5 to 8 of Table 2).
4.3 Conditional on a good pre-fit
Finally, note that Abadie et al. (2010) and Abadie et al. (2015) suggest that the SC estimator should not be
used if the pre-treatment fit is poor. However, when they recommend the placebo test using the tratioi test
statistic, they suggest that all placebos should be considered. In other words, tratio1 is conditional on a good
pre-treatment fit, while tratioi for i > 1 is unconditional. This may lead to over-rejection because it will be
more likely that the denominator of tratio1 should be close to zero relative to the denominator of t
ratio
i . We
evaluate now whether this might generate size distortions. We consider an homoskedastic model in which
the SC estimator is asymptotically unbiased (that is, treatment assignment is uncorrelated with common
factors). Note that this model is consistent with random assignment of the treated unit. The only difference
is that we will only consider simulations in which the pre-treatment fit for the actual SC estimator is good.
As a measure of goodness of pre-treatment fit, we consider a pre-treatment normalized mean squared error
index, as suggested in Ferman et al. (2016):
R˜2 = 1−
1
T0
∑T0
t=1 (y1t − ŷ1t)2
1
T0
∑T0
t=1 (y1t − y1)2
(14)
where y1 =
∑T0
t=1 y1t
T0
. Note that this measure is always lower than one, and it is close to one when the
pre-treatment fit is good. If this measure is equal to one, then we have a perfect fit.15
We present in Table 3 rejection rates conditional on a good pre-treatment fit for the treated unit. We
also present in this table the probability of having a good pre-treatment match. The results suggest that
the test may over-reject when the probability of finding a good match is not high. As an extreme example,
if we set a threshold for good fit as R˜ > 0.9 and look at the (T0, σ
2
 ) = (20, 0.1) case, then we would have a
15Differently from the R2 measure, this measure can be negative, which would suggest a poor pre-treatment fit.
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probability of 13% of having a good pre-treatment fit, and we would have a rejection rate of 10.3% for a 5%
test if we consider only SC estimators that provided a good pre-treatment fit. If the probability of having a
good fit is close to one (which is usually the case in the non-stationary model), then over-rejection is very
mild.
5 Conclusion
We consider the statistical properties of the placebo tests proposed in Abadie et al. (2010). We first show that
the graphical analysis based on placebos may be misleading even if we consider an infeasible SC estimator.
Then we show that, under some conditions, the placebo test that uses the ratio of the post/pre-intervention
MSPE ameliorates the problem as, under some conditions, the test statistics for all placebo runs will have
the same asymptotic marginal distribution. However, even under such conditions, we show that the test
statistics may still have some size distortions. We provide examples in which we can have size distortions even
when we consider an infeasible SC estimator that correctly reconstructs the factor loadings of the treated
unit. While the size distortions we find in these examples are relatively small, further research is necessary
to determine whether there might be examples in which size distortions could be more severe, or whether
there is a bound to the size distortions we might have in the SC placebo test, when we consider this infeasible
SC estimator. Finally, we show that, once we take into account that the SC weights are estimated, then we
can have important size distortions. This will be the case when the SC estimator is asymptotically biased,
when we have heteroskedasticity with a finite number of pre-treatment periods, and when we consider that
the SC estimator should only be used when there is a close-to-perfect pre-treatment fit.
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Table 1: Permutation test with asymptotically biased estimator
Stationary model
E[λ1t |D(1, T0) = 1, t > T0] = 1 E[λ1t |D(1, T0) = 1, t > T0] = 2
σ2 = 0.1 σ
2
 = 0.5 σ
2
 = 1 σ
2
 = 0.1 σ
2
 = 0.5 σ
2
 = 1
(1) (2) (3) (4) (5) (6)
T0 = 5 0.068 0.064 0.062 0.128 0.107 0.099
[0.001] [0.001] [0.001] [0.002] [0.002] [0.001]
T0 = 20 0.126 0.092 0.082 0.321 0.220 0.182
[0.002] [0.001] [0.001] [0.002] [0.002] [0.002]
T0 = 50 0.157 0.115 0.100 0.392 0.297 0.243
[0.002] [0.002] [0.002] [0.002] [0.002] [0.002]
T0 = 100 0.174 0.127 0.109 0.416 0.324 0.270
[0.002] [0.002] [0.002] [0.002] [0.002] [0.002]
Non-stationary model
E[λ1t |D(1, T0) = 1, t > T0] = 1 E[λ1t |D(1, T0) = 1, t > T0] = 2
σ2 = 0.1 σ
2
 = 0.5 σ
2
 = 1 σ
2
 = 0.1 σ
2
 = 0.5 σ
2
 = 1
(7) (8) (9) (10) (11) (12)
T0 = 5 0.057 0.056 0.055 0.080 0.072 0.069
[0.001] [0.001] [0.001] [0.001] [0.001] [0.001]
T0 = 20 0.073 0.066 0.063 0.121 0.104 0.096
[0.001] [0.001] [0.001] [0.002] [0.002] [0.001]
T0 = 50 0.082 0.072 0.068 0.136 0.120 0.110
[0.001] [0.001] [0.001] [0.002] [0.002] [0.002]
T0 = 100 0.090 0.080 0.075 0.142 0.127 0.118
[0.001] [0.001] [0.001] [0.002] [0.002] [0.002]
Notes: this table presents MC simulations results on a permutation test where the SC estimator
is asymptotically biased. Columns 1 to 6 present results for a stationary model, while columns
7 to 12 present results for a model with both non-stationary and stationary common factors.
Standard errors in brackets.
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Table 2: Permutation Test with Heteroskeadsticity
Stationary model Non-stationary model
without serial with 0.9 serial without serial with 0.9 serial
correlation correlation correlation correlation
tratioi t˜i t
ratio
i t˜i t
ratio
i t˜i t
ratio
i t˜i
(1) (2) (3) (4) (5) (6) (7) (8)
T0 = 5 0.137 - 0.240 - 0.116 - 0.186 -
[0.002] - [0.003] - [0.002] - [0.003] -
T0 = 20 0.089 0.082 0.178 0.158 0.076 0.071 0.136 0.117
[0.002] [0.002] [0.003] [0.003] [0.002] [0.002] [0.002] [0.002]
T0 = 50 0.071 0.070 0.129 0.118 0.061 0.058 0.108 0.091
[0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002]
T0 = 100 0.062 0.063 0.104 0.092 0.057 0.053 0.093 0.080
[0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002]
T0 = 1000 0.050 0.050 0.071 0.054 0.048 0.048 0.072 0.053
[0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002] [0.002]
Notes: this table presents rejection rates when the variance of the transitory shocks for the treated unit is 0.1
while the variance of the transitory shocks for the control unit is 1. Columns 1 and 2 consider the stationary
model when the common factor is serially uncorrelated using, respectively, the test statistic suggested in Abadie
et al. (2010) and the one suggested in equation 8. Columns 3 and 4 present results when the serial correlation
of the common factor is 0.9. Columns 5 to 8 present results for the non-stationary model. It is not possible to
calculate t˜i with T0 = 5. Standard errors in brackets.
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Table 3: Conditional Permutation Test
Stationary model Non-stationary model
σ2 = 0.1 σ
2
 = 0.5 σ
2
 = 1 σ
2
 = 0.1 σ
2
 = 0.5 σ
2
 = 1
(1) (2) (3) (4) (5) (6)
Panel i: conditional on R˜2 > 0.8
T0 = 5 0.068 0.099 0.105 0.059 0.081 0.091
[0.000] [0.001] [0.001] [0.000] [0.001] [0.001]
(0.732) (0.504) (0.474) (0.848) (0.614) (0.546)
T0 = 20 0.059 0.222 0.395 0.050 0.064 0.081
[0.000] [0.006] [0.022] [0.000] [0.001] [0.001]
(0.644) (0.013) (0.001) (0.982) (0.556) (0.296)
T0 = 50 0.056 0.240 - 0.050 0.052 0.056
[0.000] [0.085] - [0.000] [0.000] [0.000]
(0.703) (0.000) (0.000) (1.000) (0.832) (0.552)
T0 = 100 0.054 - - 0.050 0.050 0.052
[0.000] - - [0.000] [0.000] [0.000]
(0.767) (0.000) (0.000) (1.000) (0.972) (0.819)
Panel ii: conditional on R˜2 > 0.9
T0 = 5 0.101 0.159 0.168 0.074 0.122 0.141
[0.001] [0.001] [0.001] [0.001] [0.001] [0.001]
(0.489) (0.313) (0.296) (0.668) (0.405) (0.352)
T0 = 20 0.103 0.302 0.000 0.054 0.086 0.122
[0.001] [0.063] [0.000] [0.000] [0.001] [0.002]
(0.130) (0.000) (0.000) (0.841) (0.194) (0.062)
T0 = 50 0.109 - - 0.050 0.057 0.063
[0.003] - - [0.000] [0.001] [0.001]
(0.035) (0.000) (0.000) (0.985) (0.445) (0.189)
T0 = 100 0.105 - - 0.050 0.052 0.054
[0.007] - - [0.000] [0.000] [0.001]
(0.005) (0.000) (0.000) (1.000) (0.738) (0.439)
Notes: this table presents rejection rates conditional on the a good pre-treatment fit for the
treated unit. Columns 1 to 3 present results for the stationary model, while columns 4 to
6 present results for the non-stationary model. Panel i defines good pre-treatment fit as a
R˜2 > 0.8 for the regression of the pre-treatment outcomes of the treated unit on the pre-
treatment outcomes of the SC unit. Panel ii defines good pre-treatment fit as R˜2 > 0.9. In
parenthesis, we present the probability of having a good match. Standard errors in brackets.
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A Supplemental Appendix: Placebo Tests for Synthetic Controls
A.1 Permutation test
We now prove that that the test statistic t˜i has, asymptotically, the same expected value and variance for
all permutations. We have that:
t˜i =
1
T−T0
T∑
t=T0+1
[
yit −
∑
j 6=i
ŵji yjt
]2
− Ê [Si]√
̂V ar [Si]
where Si =
1
T−T0
T∑
t=T0
[
it −
∑
j 6=i
wji jt + λt
(
µi −
∑
j 6=i
wjiµj
)]2
. We use T − T0 blocks of a combination of
pre-treatment variables defined by P̂ik =
1
T−T0
k+T−T0−1∑
s=k
(
yis −
∑
j 6=i
ŵji yjs
)2
for k = 1, ..., 2T0 − T . In this
case, the expectation of Si is estimated by:
Ê [Si] =
1
2T0 − T
2T0−T∑
k=1
[
P̂ik
]
and the estimator of the variance is:
̂V ar [Si] =
1
2T0 − T
2T0−T∑
k=1
[
P̂ik − Ê [Si]
]2
We need to impose the following assumptions. Consider the sequence {Pik}2T0−Tk=1 . We assume that:
1. Pik is a covariance-stationary sequence.
2. Pik is α-mixing with size − rr−1 , r > 4.
3. E
[
|Pik|r+δ
]
< ∆ < 0 for some δ > 0 at all s.
4. 1T0
∑T0
s=1 P
2
ik →p E
[
P 2ik
]
Lemma 1 Under assumptions 1-5, and assuming that ŵji →p wji , then we have that the expected value of
the asymptotic distribution of t˜i is equal to zero and the asymptotic variance is equal to 1.
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Proof. Using the result that ŵji →p wji ,
1
2T0 − T
2T0−T∑
k=1
[
P̂ik
]
=
1
2T0 − T
2T0−T∑
k=1
[Pik] + op (1)
Under assumptions 1-5, and using Corollary 3.48 in White(1999),
1
2T0 − T
2T0−T∑
k=1
[
P̂ik
]
→p E [Pik] = E
 1
T − T0
T∑
t=T0
yis −∑
j 6=i
wjiyjs
2

Under assumption 2 in the main text,
E
 1
T − T0
T∑
t=T0
yis −∑
j 6=i
wjiyjs
2
 = E

yis −∑
j 6=i
wjiyjs
2

Using the model for yis and under the condition that
J+1∑
j=2
wji = 1 ,
E

yis −∑
j 6=i
wjiyjs
2
 = E

is −∑
j 6=i
wji js + λs
µis −∑
j 6=i
wjiµj
2

At the end,
Ê [S]→p E [S]
Using a proof analogous to the lemma above, we can show that V̂ ar [S]→p V ar [S].
Therefore:
t˜i →d
1
T−T0
T∑
t=T0+1
(
εit −
∑
j 6=i
wjiεjt + λt
(
µi −
∑
j 6=i
wjiµj
))2
− E
 1
T−T0
T∑
t=T0+1
(
εit −
∑
j 6=i
wjiεjt + λt
(
µi −
∑
j 6=i
wjiµj
))2
√√√√√V ar
 1
T−T0
T∑
t=T0+1
(
εit −
∑
j 6=i
wjiεjt + λt
(
µi −
∑
j 6=i
wjiµj
))2
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